UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Clinical use of neuromuscular blocking agents in critically ill patients

Author
Edward A Bittner, MD, PhD, MSEd, FCCM
Section Editor
Polly E Parsons, MD
Deputy Editors
Geraldine Finlay, MD
Marianna Crowley, MD

INTRODUCTION

Neuromuscular blocking agents (NMBAs) paralyze skeletal muscles by blocking the transmission of nerve impulses at the myoneural junction. NMBAs may be useful in the intensive care unit (ICU) for several indications.

The clinical use, administration, and potential adverse effects of NMBAs in critically ill patients will be discussed here. The pharmacology of NMBAs and use in patients undergoing anesthesia, and intubation in the emergency department, are discussed separately. (See "Clinical use of neuromuscular blocking agents in anesthesia" and "Neuromuscular blocking agents (NMBAs) for rapid sequence intubation in adults outside of the operating room".)

CLASSIFICATION AND MECHANISM OF ACTION

Neuromuscular blocking agents (NMBAs) (table 1) block the binding of acetylcholine (ACh) to the motor endplate. They are divided into depolarizing or nondepolarizing agents based upon their mechanism of action [1-4].

Depolarizing NMBAs bind to cholinergic receptors on the motor endplate, causing initial depolarization on the endplate membrane followed by blockade of neuromuscular transmission. Succinylcholine is the only depolarizing agent available in the United States and is utilized almost exclusively to facilitate intubation or treat laryngospasm [3,5].

Nondepolarizing NMBAs competitively inhibit the ACh receptor on the motor endplate. Drug binding to the ACh receptor either prevents the conformational change in the receptor or physically obstructs the ion channels so that an endplate potential is not generated [6,7]. Nondepolarizing NMBAs are divided into aminosteroid compounds (eg, pancuronium, vecuronium, rocuronium) and benzylisoquinolinium compounds (eg, atracurium, cisatracurium, mivacurium).

                           
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Oct 25, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Wheeler AP. Sedation, analgesia, and paralysis in the intensive care unit. Chest 1993; 104:566.
  2. Topulos GP. Neuromuscular blockade in adult intensive care. New Horiz 1993; 1:447.
  3. Durbin CG Jr. Neuromuscular blocking agents and sedative drugs. Clinical uses and toxic effects in the critical care unit. Crit Care Clin 1991; 7:489.
  4. Prielipp RC, Coursin DB. Applied pharmacology of common neuromuscular blocking agents in critical care. New Horiz 1994; 2:34.
  5. Elliot JM, Bion JF. The use of neuromuscular blocking drugs in intensive care practice. Acta Anaesthesiol Scand Suppl 1995; 106:70.
  6. Hanson CW 3rd. Pharmacology of neuromuscular blocking agents in the intensive care unit. Crit Care Clin 1994; 10:779.
  7. Martyn JA, Fagerlund MJ, Eriksson LI. Basic principles of neuromuscular transmission. Anaesthesia 2009; 64 Suppl 1:1.
  8. Murray MJ, DeBlock H, Erstad B, et al. Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Crit Care Med 2016; 44:2079.
  9. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 2017; 45:486.
  10. deBacker J, Hart N, Fan E. Neuromuscular Blockade in the 21st Century Management of the Critically Ill Patient. Chest 2017; 151:697.
  11. Rhoney DH, Murry KR. National survey of the use of sedating drugs, neuromuscular blocking agents, and reversal agents in the intensive care unit. J Intensive Care Med 2003; 18:139.
  12. Mehta S, Burry L, Fischer S, et al. Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. Crit Care Med 2006; 34:374.
  13. Payen JF, Chanques G, Mantz J, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a prospective multicenter patient-based study. Anesthesiology 2007; 106:687.
  14. Gill KV, Voils SA, Chenault GA, Brophy GM. Perceived versus actual sedation practices in adult intensive care unit patients receiving mechanical ventilation. Ann Pharmacother 2012; 46:1331.
  15. Duvaldestin P, Agoston S, Henzel D, et al. Pancuronium pharmacokinetics in patients with liver cirrhosis. Br J Anaesth 1978; 50:1131.
  16. Veitenhansl M, Stegner K, Hierl FX, et al. 40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004. Diabetologia 2004; 47:A1.
  17. Khalil M, D'Honneur G, Duvaldestin P, et al. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology 1994; 80:1241.
  18. Craig RG, Hunter JM. Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia 2009; 64 Suppl 1:55.
  19. Sakamoto H, Takita K, Kemmotsu O, et al. Increased sensitivity to vecuronium and prolonged duration of its action in patients with end-stage renal failure. J Clin Anesth 2001; 13:193.
  20. Lee LA, Athanassoglou V, Pandit JJ. Neuromuscular blockade in the elderly patient. J Pain Res 2016; 9:437.
  21. Hunter JM. New neuromuscular blocking drugs. N Engl J Med 1995; 332:1691.
  22. Liu X, Kruger PS, Weiss M, Roberts MS. The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. Br J Clin Pharmacol 2012; 73:741.
  23. Heier T, Caldwell JE. Impact of hypothermia on the response to neuromuscular blocking drugs. Anesthesiology 2006; 104:1070.
  24. Kisor DF, Schmith VD. Clinical pharmacokinetics of cisatracurium besilate. Clin Pharmacokinet 1999; 36:27.
  25. Berger I, Waldhorn RE. Analgesia, sedation and paralysis in the intensive care unit. Am Fam Physician 1995; 51:166.
  26. Farquhar-Mayes A. Ethical considerations in the use of neuromuscular blockades. Crit Care Nurs Q 1995; 18:13.
  27. Isenstein DA, Venner DS, Duggan J. Neuromuscular blockade in the intensive care unit. Chest 1992; 102:1258.
  28. Ellender, PJ. The use of neuromuscular blocking agents in ICU patients. Hosp Pharm 1994; 29:36.
  29. Rose JB, Theroux MC, Katz MS. The potency of succinylcholine in obese adolescents. Anesth Analg 2000; 90:576.
  30. Pühringer FK, Keller C, Kleinsasser A, et al. Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol 1999; 16:507.
  31. Pühringer FK, Khuenl-Brady KS, Mitterschiffthaler G. Rocuronium bromide: time-course of action in underweight, normal weight, overweight and obese patients. Eur J Anaesthesiol Suppl 1995; 11:107.
  32. Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, et al. Anthropometric variables as predictors for duration of action of atracurium-induced neuromuscular block. Anesth Analg 1996; 83:1076.
  33. Schwartz AE, Matteo RS, Ornstein E, et al. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesth Analg 1992; 74:515.
  34. Suzuki T, Masaki G, Ogawa S. Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. Br J Anaesth 2006; 97:160.
  35. Dulin PG, Williams CJ. Monitoring and preventive care of the paralyzed patient in respiratory failure. Crit Care Clin 1994; 10:815.
  36. Lagneau F, D'honneur G, Plaud B, et al. A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients. Intensive Care Med 2002; 28:1735.
  37. Gainnier M, Roch A, Forel JM, et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med 2004; 32:113.
  38. Forel JM, Roch A, Marin V, et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med 2006; 34:2749.
  39. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363:1107.
  40. Rudis MI, Guslits BG, Zarowitz BJ. Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit. Ann Pharmacother 1996; 30:165.
  41. Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? Crit Care Med 2013; 41:1332.
  42. Kleinpell R, Bedrosian C, McCormick L, et al. Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU. Am J Crit Care 1996; 5:449.
  43. Shapiro BA, Warren J, Egol AB, et al. Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: an executive summary. Society of Critical Care Medicine. Crit Care Med 1995; 23:1601.
  44. Sessler CN. Train-of-four to monitor neuromuscular blockade? Chest 2004; 126:1018.
  45. Rudis MI, Sikora CA, Angus E, et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 1997; 25:575.
  46. Strange C, Vaughan L, Franklin C, Johnson J. Comparison of train-of-four and best clinical assessment during continuous paralysis. Am J Respir Crit Care Med 1997; 156:1556.
  47. Baumann MH, McAlpin BW, Brown K, et al. A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis. Chest 2004; 126:1267.
  48. Phillips MS, Williams RL. Improving the safety of neuromuscular blocking agents: a statement from the USP Safe Medication Use Expert Committee. Am J Health Syst Pharm 2006; 63:139.
  49. Schaller SJ, Fink H. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evid 2013; 8:57.
  50. Welliver M, Cheek D, Osterbrink J, McDonough J. Worldwide experience with sugammadex sodium: implications for the United States. AANA J 2015; 83:107.
  51. Shalansky, KF, Shalansky, SJ. Selection and monitoring of muscle relaxants during mechanical ventilation. Can J Hosp Pharm 1992; 45:47.
  52. Mertes PM, Laxenaire MC, GERAP. [Anaphylactic and anaphylactoid reactions occurring during anaesthesia in France. Seventh epidemiologic survey (January 2001-December 2002)]. Ann Fr Anesth Reanim 2004; 23:1133.
  53. Mertes PM, Tajima K, Regnier-Kimmoun MA, et al. Perioperative anaphylaxis. Med Clin North Am 2010; 94:761.
  54. Raps EC, Bird SJ, Hansen-Flaschen J. Prolonged muscle weakness after neuromuscular blockade in the intensive care unit. Crit Care Clin 1994; 10:799.
  55. Partridge BL, Abrams JH, Bazemore C, Rubin R. Prolonged neuromuscular blockade after long-term infusion of vecuronium bromide in the intensive care unit. Crit Care Med 1990; 18:1177.
  56. Price DR, Mikkelsen ME, Umscheid CA, Armstrong EJ. Neuromuscular Blocking Agents and Neuromuscular Dysfunction Acquired in Critical Illness: A Systematic Review and Meta-Analysis. Crit Care Med 2016; 44:2070.
  57. LeBlanc JM, Dasta JF, Pruchnicki MC, et al. Bispectral index values, sedation-agitation scores, and plasma Lorazepam concentrations in critically ill surgical patients. Am J Crit Care 2012; 21:99.